What is Intellia Therapeutics Inc (NTLA) stock price today?

Intellia Therapeutics Inc (NTLA) currently trades at $13.48 per share. The stock has a market capitalization of $1.48B and a P/E ratio of —x.

Is NTLA stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Intellia Therapeutics Inc has a Smart Value Score of 35/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -1.47.

What is Intellia Therapeutics Inc's revenue and earnings?

Intellia Therapeutics Inc has trailing twelve-month (TTM) revenue of $67.67M with profit margins of 0.00%. Earnings per share (EPS) is $-3.81.

Is Intellia Therapeutics Inc financially healthy?

Intellia Therapeutics Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -1.47 places it in the distress.

NTLA

Intellia Therapeutics Inc

NASDAQ: NTLA · HEALTHCARE · BIOTECHNOLOGY

$13.48

+8.32% today

Updated 2026-04-30

Market cap

$1.48B

P/E ratio

—

P/S ratio

21.87x

EPS (TTM)

$-3.81

Dividend yield

—

52W range

$7 – $28

Volume

5.1M

Market cap

$1.48B

P/E ratio

—

P/S ratio

21.87x

EPS (TTM)

$-3.81

Dividend yield

—

52W range

$7 – $28

Volume

5.1M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

6.7

Growth

6.5

Quality

2.5

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-1.5

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$26.86

+99.26%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy13 Buy9 Hold1 Sell1 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 78.80% QoQ

+ Debt/equity 0.13x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -1.47 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-69.41M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$52.12M	$36.27M	$57.88M	$67.67M	$67.67M
Net income	$-474.19M	$-481.19M	$-519.02M	$-412.69M	$-95.79M
EPS	—	—	—	—	$-3.81
Free cash flow	$-391.68M	$-408.07M	$-354.66M	$-354.66M	$-69.41M
Profit margin	-909.78%	-1,326.51%	-896.77%	-609.85%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NTLA	$1.48B	35	6.7	2.5	5.0	6.5	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Intellia Therapeutics Inc trades at $13.48. Our Smart Value Score of 35/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -1.47, it sits in the distress. TTM revenue stands at $67.67M.

Frequently asked questions

What is Intellia Therapeutics Inc's stock price?

Intellia Therapeutics Inc (NTLA) trades at $13.48.

Is Intellia Therapeutics Inc overvalued?

Smart Value Score 35/100 (Grade D, Sell).

What is the price target of Intellia Therapeutics Inc (NTLA)?

The analyst target price is $26.86, representing +99.3% upside from the current price of $13.48.

What is Intellia Therapeutics Inc's revenue?

TTM revenue is $67.67M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-1.47 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.intelliatx.com

Quick metrics

P/S ratio21.87x

ROE-53.50%

Beta1.99

50D MA$13.60

200D MA$13.14

Shares out0.12B

Float0.11B

Short ratio—

Avg volume5.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

NTLA vs LLY →NTLA vs JNJ →NTLA vs ABBV →Stock screener →